ChemicalBook >> CAS DataBase List >>Sorafenib tosylate

Sorafenib tosylate

CAS No.
475207-59-1
Chemical Name:
Sorafenib tosylate
Synonyms
CL050;Sorafenib &Sorafeni tosylate;Sorafinib mesylate;SORAFENIB TOSYLATE;Sorafenib (Nexavar);Sorafenib TsOH salt;Sorafenib 475207-59-1;Sorafenib tosylate API;BAY 43-9006;BAY43-9006
CBNumber:
CB92131200
Molecular Formula:
C21H16ClF3N4O3.C7H8O3S
Molecular Weight:
637.03
MDL Number:
MFCD08235032
MOL File:
475207-59-1.mol
MSDS File:
SDS
Last updated:2024-03-19 09:49:01

Sorafenib tosylate Properties

Melting point 229-232°C
storage temp. 2-8°C(protect from light)
solubility Soluble in DMSO (up to 200 mg/ml) or in Ethanol (up to 3 mg/ml).
form solid
color Off-white
Stability Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 1 month.
InChIKey IVDHYUQIDRJSTI-UHFFFAOYSA-N
SMILES S(C1C=CC(C)=CC=1)(O)(=O)=O.O(C1C=CC(NC(=O)NC2C=CC(Cl)=C(C(F)(F)F)C=2)=CC=1)C1=CC=NC(C(=O)NC)=C1
CAS DataBase Reference 475207-59-1(CAS DataBase Reference)
FDA UNII 5T62Q3B36J
NCI Dictionary of Cancer Terms sorafenib tosylate
NCI Drug Dictionary sorafenib tosylate

SAFETY

Risk and Safety Statements

Symbol(GHS)  GHS hazard pictogramsGHS hazard pictograms
GHS08,GHS09
Signal word  Danger
Hazard statements  H360FD-H362-H372-H410
Precautionary statements  P201-P202-P260-P263-P273-P308+P313
Risk Statements  36/37/38
Safety Statements  28-26
HS Code  29159000
NFPA 704
0
3 0

Sorafenib tosylate price

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich Y0002236 Sorafenib for peak identification European Pharmacopoeia (EP) Reference Standard 475207-59-1 Y0002236 $202 2024-03-01 Buy
Sigma-Aldrich Y0002224 Sorafenib tosilate CRS, European Pharmacopoeia (EP) Reference Standard 475207-59-1 Y0002224 $202 2024-03-01 Buy
Sigma-Aldrich SML2633 Sorafenib tosylate ≥98% (HPLC) 475207-59-1 50MG $48.2 2024-03-01 Buy
TRC S676845 SorafenibTosylate 475207-59-1 100mg $45 2021-12-16 Buy
Usbiological 289038 Sorafenib tosylate 475207-59-1 1g $440 2021-12-16 Buy
Product number Packaging Price Buy
Y0002236 Y0002236 $202 Buy
Y0002224 Y0002224 $202 Buy
SML2633 50MG $48.2 Buy
S676845 100mg $45 Buy
289038 1g $440 Buy

Sorafenib tosylate Chemical Properties,Uses,Production

Indications and Usage

Sorafenib tosylate is a new type of multi-target antitumor drug, was developed by the German Bayer Pharmaceuticals, and displayed expansive antitumor activity in preclinical animal tests. Sorafenib tosylate is mainly used in advanced liver cancer treatment and is well tolerated.

Mechanisms of Action

Sorafenib tosylate can simultaneously affect tumor cells and tumor blood vessels. It has a double antitumor effect: it can block the cell signal transduction pathways mediated by RAF/MEK/ERK to directly inhibit tumor cell growth, while also inhibiting VEGF and platelet derived growth factors (PDGF) receptors to prevent the formation of new tumor blood vessels, thus indirectly inhibiting tumor cell growth.

Clinical Research

In a stage three randomized clinical study of American and European treatments for advanced kidney cancer, 903 cases advanced kidney patients who had experienced one unsuccessful systematic treatment (biological immunity or chemotherapy) were randomly split into two groups. One group received sorafenib tosylate, while the other received a placebo. Mid-term analysis found already 222 deaths and the objective efficacy of the two groups to be 10% and 2%, while 74% and 53% of patients had stabilized conditions. The sorafenib tosylate group’s survival period was longer than that of the placebo group, with the risk ratio as 0.72. However, this different does not have statistical significance, as this is only a mid-term analysis, and final analysis after treatment will yield the correct survival period comparison.
602 advanced liver cancer patients selected from the USA, Europe, Australia, and other countries and areas, who did not receive systematic treatment, were included in a study. Results showed that compared to the placebo, taking sorafenib tosylate could extend their total survival period of patients with late stage or primary liver cancer by about 44% and their extend disease progression period by about 73%.

Adverse reactions

Manageable diarrhea, rashes, fatigue, hand-foot syndrome, hypertension, alopecia, nausea, vomiting, and loss of appetite.

Description

Sorafenib (475207-59-1) was initially developed as a Raf kinase inhibitor, IC50 = 6 nM, but has been shown to inhibit many receptor tyrosine kinases including BRAF (IC50 = 22 nM); VEGFR-2 (IC50 = 90 nM); VEGFR-3 (IC50 = 20 nM); PDGFR-β (IC50 = 57 nM); Flt3 (IC50 = 58 nM); c-KIT (IC50 = 68 nM); FGFR-1 (IC50 = 580 nM).1?Paradoxically more potent in a cellular assay (IC50 = 20 nM) compared to an isolated enzyme assay (IC50 = 107 nM) for c-Fms.2?Inhibits activation of MAPK pathway and ERK phosphorylation.3?Induces caspase-independent apoptosis in melanoma cells.4?Sorafenib is a clinically useful anticancer agent.

Uses

Sorafenib Tosylate (Bay 43-9006, Nexavar) is a small molecular inhibitor of VEGFR, PDGFR, c-Raf and B-Raf with IC50s of 18 nM, 10 nM, 3 nM and 15 nM, respectively.

Definition

ChEBI: Sorafenib tosylate is an organosulfonate salt. It contains a sorafenib.

brand name

Nexavar (Bayer).

General Description

Sorafenib is available in 200-mg tablets for oral administrationand is used in the treatment of RCC and colon cancer.The agent is classified as a multikinase inhibitor because ofits action on numerous kinase enzymes including thePDGF-R, VEGF-R, Kit, and Raf. Sorafenib is 39% to 48% bioavailable and CYP3A4-mediated metabolism giveseight identified metabolites including the N-oxide, which isequally active with the parent. However, the majority of thedrug in plasma is present as the parent compound.Sorafenib is highly protein bound (99.5%). The drug iseliminated primarily in the feces (77%) with 19% appearingin the urine as glucuronides (UGT1A1) and has a eliminationhalf-life of 24 to 48 hours. The most commonly seentoxicity is skin rash that normally occurs within the first6 weeks of therapy. Other adverse effects include hypertension,fatigue, increased wound healing time, and increasedrisk of bleeding.

Clinical Use

Sorafenib is used to treat late-stage kidney cancer (advanced renal cell carcinoma), liver cancer (hepatocellular carcinoma) that cannot be treated by surgery, and differentiated thyroid cancer that has come back or spread to other parts of your body. Sorafenib is an antineoplastic (cancer) agent. It interferes with the growth of cancer cells, which are eventually destroyed by the body.

Side effects

The side effects of Sorafenib tosylate include Bleeding gums, blistering, peeling, redness, or swelling of the palms of the hands or bottoms of the feet, bloating of the abdomen or stomach, blood in the urine or stools, clay-colored stools, coughing up blood, difficulty with breathing or swallowing, increased menstrual flow or vaginal bleeding.

target

Raf-1

References

1) Wilhelm et al. (2004), BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis; Cancer Res., 64 7099 2) Guo et al. (2006), Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors; Mol. Cancer Ther., 5 1007 3) Wilhelm et al. (2003), The novel Raf inhibitor BAY 43-9006 blocks signaling and proliferation in BRAF mutant and wildtype melanoma and colorectal tumor cell lies; Proc. Am. Assoc. Cancer Res., 44 106609 4) Panka et al. (2006), The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells; Cancer Res., 66 1611

Sorafenib tosylate Preparation Products And Raw materials

Raw materials

Preparation Products

Global( 547)Suppliers
Supplier Tel Email Country ProdList Advantage
Huadong Medicine (Xi'an)Bodyguard Pharmaceutical Co.,Ltd.
+86-029-86185165 +8618629664246 guoyuan@eastchinapharm.com China 1600 58
Yangzhou Qinyuan Pharmatech Co.,ltd
+86-18752526868 jennysun@yzqyyykj.com China 64 58
Zibo Wei Bin Import & Export Trade Co. Ltd.
+86-0533-2091136 +8613864437655 ziboweibinmaoyi@163.com China 100 58
shan dong Fengjin Pharmaceutical company
+8615066764791 liangfulin@fengjin-pharma.com China 8 58
Shanghai UCHEM Inc.
+862156762820 +86-13564624040 sales@myuchem.com China 6506 58
Changzhou Rokechem Technology Co., Ltd.
18758118018 sales001@rokechem.com China 255 58
shandong perfect biotechnology co.ltd
+86-53169958659; +8618596095638 sales@sdperfect.com China 294 58
Henan Bao Enluo International TradeCo.,LTD
+86-17331933971 +86-17331933971 deasea125996@gmail.com China 2504 58
Frapp's ChemicalNFTZ Co., Ltd.
+86 (576) 8169-6106 sales@frappschem.com China 885 50
Capot Chemical Co.,Ltd.
571-85586718 +8613336195806 sales@capotchem.com China 29797 60

Related articles

  • About Sorafenib tosylate
  • Sorafenib is used to treat kidney, liver, and thyroid cancer. It is a chemotherapy drug that works by slowing or stopping the ....
  • Aug 14,2019

View Lastest Price from Sorafenib tosylate manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
Sorafenib tosylate pictures 2024-03-19 Sorafenib tosylate
475207-59-1
US $100.00 / kg 1kg 99% 1t Zibo Wei Bin Import & Export Trade Co. Ltd.
Sorafenib tosylate pictures 2024-03-19 Sorafenib tosylate
475207-59-1
US $100.00-95.00 / kg 1kg 99.99% 100Tons Hebei Dangtong Import and export Co LTD
Sorafenib Tosylate pictures 2024-03-12 Sorafenib Tosylate
475207-59-1
US $0.00 / g 1g 98% HPLC 1kg shandong perfect biotechnology co.ltd
  • Sorafenib tosylate pictures
  • Sorafenib tosylate
    475207-59-1
  • US $100.00 / kg
  • 99%
  • Zibo Wei Bin Import & Export Trade Co. Ltd.
  • Sorafenib tosylate pictures
  • Sorafenib tosylate
    475207-59-1
  • US $100.00-95.00 / kg
  • 99.99%
  • Hebei Dangtong Import and export Co LTD

Sorafenib tosylate Spectrum

SORAFENIB TOSYLATE Sorafenib & its intermediates Sorafinib mesylate 4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide monomethanesulfonate Sorafenib Tosylate(Bay 43-9006,Nexavar) 2-PyridinecarboxaMide, 4-[4-[[[[4-chloro-3-(trifluoroMethyl)phenyl]aMino]carbonyl]aMino]phenoxy]-N-Methyl-, 4-Methylbenzenesulfonate Sorafenib Tosylate (Nexavar) Sorafenib (Nexavar) Sorafenib tosylate API 1-(4-Chloro-3-(trifluoroMethyl)phenyl)-3-(4-((2- (MethylcarbaMoyl)pyridin-4-yl)oxy)phenyl)urea Mono(4- Methylbenzenesulfonate) 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) Sorafenib TsOH salt Sorafenib, p-Toluenesulfonate Salt, >99% Sorafenib & Sorafenib tosylate, >=99% 4-[4-[[[[4-chloro-3-((trifluoromethyl))phenyl]amino]carbonyl]amino]phenoxy]-N-methylpyridin-2-carboxamide tosylate (1:1) 4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(pyridin-3-yl)pyrim Sorafeni tosylate SORAFENIB TOSYLATE (BAY 43-9006 TOSYLATE) BAY 43-9006;BAY43-9006 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N2-methylpyridine-2-carboxamide mono (4-methylbenzenesulfonate) Sorafenib (BAY-43-9006) Sorafenib 475207-59-1 Sorafenib tosylate-002 Sorafenib tosylate(Nexavar,SORENIC) N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea Tolsylate Sorafenib Tolsylate N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea Tolsylate CL050 Sorafenib degradation (Sorafenib) 4-[4-[[4-Chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-2-pyridinecarboxamide Tosylate 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N2-methylpyridine-2-carboxamide mono (4-methylbenzenesulfonate)c Sorafenib tosylate USP/EP/BP Sorafenib Tosylate (MFDS) Bay 43-9006 (Tosylate) Sorafenib Tosylate (Bay 43-9006 Sorafenib tosylateQ: What is Sorafenib tosylate Q: What is the CAS Number of Sorafenib tosylate Q: What is the storage condition of Sorafenib tosylate Q: What are the applications of Sorafenib tosylate Sorafenib toluene sulfonate 1,8-Butanediol,monomethanesulfonate 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-methylpicolinamide 4-methylbenzenesulfonate Pinacolborane Impurity 11 Toluenesulfonic acid sorafenib 475207-59-1 C21H16ClF3N4O3C7H8SO C21H16ClF3N4O3C7H8O3S C29H26F3N7O4S C28H24ClF3N4O6S Bay 43-9006 Inhibitors MAPK API